Inotiv (NOTV) Q4 2024 earnings summary

Executive summary

• Fiscal Q4 2024 revenue was $130.4M, up 23% sequentially but down 7.3% year-over-year, with volatility driven by the NHP business and conservative biotech spending.

• Fiscal 2024 revenue declined 14.3% year-over-year to $490.7M.

• Operating loss improved sequentially to $13.2M in Q4, but worsened year-over-year due to lower NHP and DSA margins.

• Net loss for FY 2024 was $108.9M, or 22.2% of revenue, compared to $104.9M, or 18.3% of revenue, in FY 2023.

• Initiatives to reduce risk, improve customer experience, and enhance cash flow were implemented, including site consolidation and facility improvements.

Financial highlights

• Q4 2024 consolidated revenue: $130.4M (up from $105.8M in Q3, down from $140.7M in Q4 2023).

• Q4 net loss attributable to shareholders: $18.9M ($0.73/share), compared to $9.7M ($0.38/share) in Q4 2023.

• Adjusted EBITDA for Q4: $5.4M (4.1% margin), down from $23.7M (16.8%) in Q4 2023.

• FY 2024 Adjusted EBITDA: $18.2M (3.7% margin), down from $65.8M (11.5%) in FY 2023.

• Cash and equivalents at year-end: $21.4M; total debt: $393.3M.

Outlook and guidance

• No formal FY 2025 guidance provided; management expects improved RMS margins in 2025 as higher-cost NHP inventory is cleared.

• Pre-sales of NHPs for 2025 are stronger than prior year, with recurring revenue from colony management services expected to grow 20-25%.

• Adjusted EBITDA margin target of 18-22% remains a midterm goal, contingent on industry recovery.

• Growth anticipated in NHP, diet, bedding, enrichment, and potentially discovery services in 2025, mainly from volume rather than pricing.

• Fiscal 2025 will see the next phase of site optimization, projected to eliminate $4–5M in operating expenses, with most benefits expected in fiscal 2026.